Device Trial Radar · NCT01957787
Study of Cryoablation for Metastatic Lung Tumors
Last checked: Nov 19, 2026Latest source record: Jul 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Apr 10, 2014
Primary completion
Mar 9, 2017
Study completion Aug 20, 2018
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Oct 8, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of cryoablation therapy used to treat tumors in participants with pulmonary metastatic disease. This study is to enroll participants who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5 centimeter (cm). Participants will be followed 24 months post their cryoablation procedure.
Conditions
- Neoplasm Metastasis
Interventions
CryoablationDevice
Application of extremely cold temperatures to the identified tumor(s).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 12Time frame: Month 1 (Month 3 if Month 1 Data was missing) and Month 12
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
UCLA Ronald Reagan Medical Center
Los Angeles, California
Cancer Treatment Centers of America at Southeastern Regional Medical Center
Newnan, Georgia
Mayo Clinic Rochester
Rochester, Minnesota
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.